-
CanSino announces clinical data on inhaled and intramuscular vaccines
Time of Update: 2023-02-03
(2) ImmunogenicityThe test results of the original true virus neutralizing antibody showed that on the basis that the level of the pre-antibody was close to negative, the GMT of the inhaled antibody reached 672 28 days after the booster vaccination, which was higher than the 583 in the intramuscular group, which was much higher 59 in the inactivated group.
-
Day One in Health Care Negotiations: A Modest Start Under Anxiousness
Time of Update: 2023-02-03
(Secret Cong Cong also contributed to this article) The most lively thing in the innovative drug industry every year is the annual medical insurance negotiation work since the establishment of the Health Insurance Bureau in 2018.
-
Gene therapy at home and abroad is looking forward to next year
Time of Update: 2023-02-03
Figure 3 Pipeline progress of gene editing companies (Source: official websites of each company; Organized by Fengshuo Venture Capital)In 2023, the first product of the leading CRISPR company will submit a rolling listing application; VCTX210/211, a synonymous β cell replacement therapy for the treatment of diabetes, by CRISPR and ViaCyte, has entered clinical trials.
-
ProQR and Eli Lilly expand RNA editing collaboration, shares jump 63%
Time of Update: 2023-02-03
75 billionOriginal English text: _mstmutation="1" _msthash="220730" _msttexthash="10499125"> On December 22, Eli Lilly and Company partnered with ProQR Therapeutics jointly announced the expansion of its licensing and collaboration agreement to expand collaboration on RNA editing technologies with a focus on the discovery, development and commercialization of new gene drugs.
-
New drugs approved by the FDA in 2022
Time of Update: 2023-02-03
Indications: Patients with relapsed or refractory follicular lymphoma after at least two lines of systemic therapyAttached: New drugs approved by the FDA in 2022 Indications: Supplemental diet and exercise to improve glycemic control in adult patients with type 2 diabetes On May 13, the FDA approved the marketing of Mounjaro (tirzepatide), a dual agonist of Eli Lilly's glucose-dependent insulin stimulating peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor.
-
Junshi VV116 Announces Phase III Clinical Data for the First Time!
Time of Update: 2023-02-03
On December 29, Junshi Biologics' oral nucleoside anti-novel coronavirus (SARS-CoV-2) drug VV116 (JT001) was head-to-head Pfizer Paxlovid Phase III clinical data on treatment with mild to moderate COV
-
$660 million! Gilead and EVOQ agree on immunotherapy
Time of Update: 2023-02-03
Original link: _mstmutation="1" _msthash="220729" _msttexthash="6888128"> EVOQ's technology is designed to enable lymphatic-targeted delivery of disease-specific antigens that have been optimized to deliver antigens to restore immune tolerance.
-
More than 350 drugs will increase in price, including Pfizer, GSK, BMS, AZ and Sanofi
Time of Update: 2023-02-03
Recently, according to Reuters, according to healthcare research company 3 Axis Advisors According to the data analyzed, multinational big pharmaceutical companies including Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca and Sanofi plan to raise 350 in the United States in early January 2023 The price of a variety of unique drugs.
-
2022 FDA Approved Drug Analysis (Part I)
Time of Update: 2023-02-03
12 Pluvicto Indications: Prostate cancerIndications: Prostate cancerR&D company: NovartisR&D company: NovartisDate of approval: 3 JanuaryDate of approval: 3 JanuaryPluvicto is approved for the treatment of adults with advanced prostate-specific membrane antigen-positive, metastatic castration-resistant prostate cancer (mCRPC) who have received androgen receptor pathway inhibitor therapy and taxane-based chemotherapy.
-
The FDA approved the listing of innovative therapies this year: TCR dual antibody, domestic CAR-T...
Time of Update: 2023-02-03
prefaceprefaceIn 3 days, 2022 will be a complete page of history. This year, we witnessed division and union, and felt the cool and hot of the world. This year, Vientiane has been updated, and the env
-
2022 inventory: A-share pharmaceutical companies rose TOP10, ibuprofen took the top spot, and 3 rose by more than 100%
Time of Update: 2023-02-03
It involves antipyretic drugs, antigen tests, new crown specific drugs, and antiviral drugsAccording to the data of Flush Finance, the top ten pharmaceutical companies (excluding medical devices, pharmaceutical businesses, and medical service companies) in A-shares in 2022 are:Xinhua Pharmaceutical, Zhongsheng Pharmaceutical, Shanghai Yizhong, Weixinkang, Rongchang Biotechnology, Haichen Pharmaceutical, Enhua Pharmaceutical, Yiling Pharmaceutical, Shuangcheng Pharmaceutical, Huatedyne.
-
2022 inventory: A-share medicine and equipment fell top 30! CanSino, Gan & Lee Pharmaceutical, Kailaiying...
Time of Update: 2023-02-03
Figure 2 Gan&Lee Pharmaceutical's stock price Image source: Jiufang ZhitouFigure 2On the one hand, subject to the rise in the cost of sales ratio, Gan&Lee Pharmaceutical has always been proud, which is comparable to Moutai's high profitability has fallen sharply this year, on the other hand, the centralized procurement of insulin "big killer" has strangled the imagination of profitability.
-
Interview with Lidi Biotech Wen Danyi: In the CRO industry in the cold winter of capital, each company has its own way of survival
Time of Update: 2023-02-03
In Wen Danyi's view, under the cold winter of capital, every domestic CRO company has its own way of survival, and in the future, the CRO industry will show a development trend of cross-integration with biotech, CDMO and other enterprises from all walks of life.
-
From the Spring Festival Gala in the pharmaceutical world, overseas "attack", to the birth of the "new crown miracle medicine"... Top ten famous scenes in the pharmaceutical industry in 2022
Time of Update: 2023-02-03
Open 2022, many "famous scenes" have swept in, and major events in the medical industry have been "stubble after stubble". "The first domestic PD-1 to break through the FDA" can be called the "Spring
-
Volume-for-price, including Pfizer Paxlovid in medical insurance negotiations/collective procurement can be a win-win situation
Time of Update: 2023-02-03
At present, there are only 2 small molecule drugs for new coronary pneumonia that have been marketed in China, including Azvudine of real biology and Paxlovid of Pfizer.
-
Metagenomi completed $275 million Series B funding to advance its gene editing pipeline
Time of Update: 2023-02-03
Thomas said: Original link: _mstmutation="1" _msthash="220731" _msttexthash="6493708"> On Jan. 5, Metagenomi, a gene drug company with a range of wholly-owned next-generation gene-editing systems, announced the closure of a $100 million Series B+ funding round by Novo Holdings, Catalio Capital Management and SymBiosis, co-led, with new and existing investor participation, including Leaps by Bayer and Moderna, as well as initial Series B investors PFM Health Sciences and Farallon Capital Management and a leading global investment firm.
-
In the new situation of coexistence with the new crown, who will become the "game breaker" of medication?
Time of Update: 2023-02-03
At the same time, the number of new crown patients increased sharply, based on the general fever symptoms after infection, two antipyretic and analgesic drugs "ibuprofen" and "acetaminophen" once held high sales, but at the end of December, the new crown oral drug azvudine jumped to the top and became the hottest "KOL": topicality, demand surged.
-
Express Disease recurrence rate reduced by nearly 50%! The innovative therapy was approved by the FDA for the treatment of multiple sclerosis
Time of Update: 2023-02-03
Targeting CD20 protein antibody Briumvi (ublituximab) for the treatment of recurrent multiple sclerosis (RMS)Recurrent multiple sclerosis is a chronic central nervous system demyelinating disease that occurs when the immune system attacks the myelin sheath that protects nerves, and consists of relapsing-remitting multiple sclerosis (RRMS) as well as secondary progressive multiple sclerosis (SPMS).
-
Spring River Plumbing CXO Prophet
Time of Update: 2023-02-03
WuXi AppTec's DDSU (Domestic New Drug R&D) business is an important window to observe the trend of domestic innovative drugs, and revenue in the first three quarters of this year fell by 27.
-
Dual antibody ADC to the stage of innovation, ambition and danger
Time of Update: 2023-02-03
Why target two epitopes at the same time?We know that the mechanism of action of ADC is that the antibody specifically binds to antigens on tumor cells and is then endocytosed by tumor cells; The drug degrades after being phagocytosed, eventually releasing toxins inside the cells to kill cancer cells.
